Medical Condition News

RSS

Life Beyond Cancer Foundation launches new Web site to help cancer patients

The Life Beyond Cancer Foundation, formerly known as the US Oncology Foundation, announced today that it has launched its new Web site at www.lifebeyondcancer.org. Touting an array of resources for cancer patients throughout the United States, the foundation's mission is to help cancer patients and their families connect with financial assistance, support programs and other necessary resources that can help them on their cancer journey.

23 Mar 2010

Imaging tests used in diagnosis of possible PE vary: Study

The imaging tests used in the diagnosis of possible pulmonary embolism (PE) vary by physician specialty and geographic region, which suggests that some of this imaging may be inappropriate, according to a study in the April issue of the American Journal of Roentgenology (www.ajronline.org).

22 Mar 2010

Treatments for preventing hamstring injuries

A brand new systematic review into the research of hamstring injuries has revealed that not enough is known about the effectiveness of current prevention methods for one of the most common sports injuries.

22 Mar 2010

Treatment options available for GAD

A little worry is normal, but people who constantly worry about daily concerns, even when times are good, may have generalized anxiety disorder.

22 Mar 2010

Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated

CyDex Pharmaceuticals, Inc. today announced the initiation of patient dosing in the company’s Phase 2A clinical trial of its Captisol-Enabled® Melphalan HCL. Melphalan is an FDA-approved chemotherapy for the palliative treatment of multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline.

22 Mar 2010

Over one-third of people with terminal cancer do not receive entitled benefits: Study

Over one-third of people with terminal cancer are not getting the benefits to which they are entitled, a study by Macmillan Cancer Support has found.

22 Mar 2010

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the formation of its Parkinson’s Disease Scientific Advisory Board (SAB), featuring some of the leading medical researchers in neurology.

22 Mar 2010

JDRF, Pfizer, Hadassah Medical Organization, The Hebrew University of Jerusalem form diabetes research collaboration

The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin a diabetes research collaboration with Pfizer, Hadassah Medical Organization, and The Hebrew University of Jerusalem on drugs to replicate and regenerate insulin-producing cells in people with type 1 diabetes.

22 Mar 2010

CRT, Cephalon to collaborate on development of small molecule inhibitors against cancer

Cancer Research Technology has announced an exclusive agreement with Cephalon, Inc., an international biotechnology company, to collaborate on the development of small molecule inhibitors. These molecules will target specific members of the 'protein kinase C' superfamily of cell signalling proteins - which have been shown to be associated with the development of cancer.

22 Mar 2010

BEMA Granisetron development program: BDSI announces positive meeting with FDA

BioDelivery Sciences International, Inc. announced the positive outcome of a meeting with the FDA on the development program for BEMA Granisetron, the company’s potential treatment for the prevention of nausea and vomiting associated with cancer therapy. FDA concurred with BDSI’s plans to pursue a development program based on clinical pharmacokinetic data for a 505(b)(2) New Drug Application.

22 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

Bakeries across the U.S. join campaign for epilepsy awareness

This week, bakeries across the United States are cooking up purple cupcakes in an effort to increase awareness about epilepsy nationwide. The Great Purple Cupcake Project is an initiative of The Anita Kaufmann Foundation -- an American epilepsy education organization and the US Sponsor of Purple Day for epilepsy awareness.

22 Mar 2010

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies.

22 Mar 2010

Dow Jones reports on side effects of Labopharm's once-daily version of Trazodone, stock falls by 5%

After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to switch from less expensive generic versions. Dow Jones found that when compared, the side effects of Labopharm's drug fare no better than the generic versions that dominate the market.

22 Mar 2010

Americans to join in Purple Day campaign to support epilepsy awareness

Members of the U.S. House and Senate, children in schools across the country, and employees of workplaces nationwide will wear purple to support epilepsy awareness on March 26. Thousands of Americans will also join the campaign by hosting Purple Day activities in their regions.

22 Mar 2010

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Arrowhead Research Corporation today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc., has demonstrated systemic delivery of siRNA and the successful “silencing” of a widely recognized cancer gene via RNA interference (RNAi) in humans.

22 Mar 2010

Simcere Pharmaceutical completes Phase IV clinical study of Endostar

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endostar (also known as Endu) in China, announced today the successful completion of Endostar Phase IV clinical study at a conference in Beijing dedicated to this study.

22 Mar 2010

FDA convenes Advisory Committee meeting to discuss safety of LABA's

On Wednesday, March 10 and Thursday, March 11, the FDA is convening an Advisory Committee meeting on the clinical trial design for long acting beta-2 adrenergic agonists.

22 Mar 2010

Gene implicated in JSRDs: UCD research team publishes new information

Researchers in University College Dublin (UCD) led by Conway Fellow, Dr Oliver Blacque have revealed new information about a gene implicated in Joubert syndrome and related cerebellar disorders (JSRDs) that are characterised by blindness, bone abnormalities, cystic kidneys, developmental delay and loss of muscle tone and control. The findings from this research, which is funded by Science Foundation Ireland, have been published today in a leading science journal, Journal of Cell Biology.

22 Mar 2010

Cancer radiotherapy can increase risk of cardiovascular disease later in life

For an as yet unknown reason, cancer radiotherapy can increase the risk of cardiovascular disease later in life, a problem that is growing as more and more people survive their cancer diagnosis. New research from Karolinska Institutet now suggests that sustained inflammation induced by post-radiotherapy changes in the gene expression in the arteries could be the cause.

22 Mar 2010